...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in lipidology >Colchicine: an affordable anti-inflammatory agent for atherosclerosis
【24h】

Colchicine: an affordable anti-inflammatory agent for atherosclerosis

机译：血清髓：用于动脉粥样硬化的实惠的抗炎剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose of review Inflammation has been shown to be central to the development and progression of atherosclerosis. Despite detailed understanding of its central role and the cellular dynamics, which contribute to atherosclerotic inflammation, there has been slow progress in finding suitable agents to treat it. The recent CANTOS trial showed that the interleukin-1β inhibitor canakinumab can improve outcomes after acute coronary syndromes. Being a monoclonal antibody, it is expensive and inconvenient to administer for long-term treatment. This review summarizes recent work in finding effective, affordable alternatives to canakinumab. Recent findings Statin drugs have anti-inflammatory properties but separating their LDL lowering effect from their anti-inflammatory effect has been difficult. Drugs acting on targets outside of the interleukin-1β (IL-1β) pathway have been tested without finding a suitable candidate. Following the proof of principle provided by the success of canakinumab, other candidates targeting the IL-1β pathway are undergoing detailed evaluation. The most likely candidates are low-dose methotrexate and low-dose colchicine. The potential mechanisms and ongoing clinical trials are described. Summary Targeting the IL-1β pathway has already been successful with canakinumab but its expense and inconvenience of administration may limit its widespread uptake for controlling inflammation in atherosclerosis. Low-dose methotrexate and low-dose colchicine are affordable and more accessible alternatives, currently undergoing detailed evaluation for safety and efficacy in large randomized controlled trials.
机译：审查目的已被证明是动脉粥样硬化的发展和进展的核心。尽管对其核心作用和蜂窝动态有助于动脉粥样硬化炎症的详细了解，但寻找合适的药剂来治疗它的核心作用和蜂窝动态。最近的Cantos试验表明，白细胞介素-1β抑制剂Canakinumab可以在急性冠状动脉综合征后改善结果。作为单克隆抗体，对长期治疗施用昂贵且不方便。本综述总结了最近在寻找罐头尼替纳布的有效，实惠的替代品方面的工作。最近发现他汀类药物具有抗炎性质，但将其LDL降低抗炎作用分离难以困难。已经测试了在白细胞介素-1β（IL-1β）途径之外的靶标的药物在不寻找合适的候选物的情况下进行了测试。追随加拿大替纳米成功提供的原则证明，靶向IL-1β途径的其他候选者正在进行详细评估。最有可能的候选物是低剂量甲氨蝶呤和低剂量血清晶氨酸。描述了潜在的机制和持续的临床试验。综述靶向IL-1β途径已经成功地用Canakinumab取得了成功，但其费用和给药的不便可能会限制其用于控制​​动脉粥样硬化中炎症的广泛吸收。低剂量甲氨蝶呤和低剂量血清曲霉是价格实惠的，更易于替代的替代品，目前正在进行详细评估大型随机对照试验中的安全性和疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号